Ilenia Valentino

Catanzaro, 88100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential.

Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 31, 2026

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities.

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities.

Journal: Cancers

Published: February 14, 2026

OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug Development.

OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug Development.

Journal: Antioxidants (Basel, Switzerland)

Published: December 22, 2025

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity.

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity.

Journal: International journal of biological macromolecules

Published: November 18, 2025

Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Journal: Journal of translational medicine

Published: November 11, 2025

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Journal: Journal of translational medicine

Published: July 01, 2025

Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma.

Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 30, 2025

Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance.

Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: June 16, 2025

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

Journal: Blood

Published: June 11, 2025

Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma.

Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma.

Journal: Haematologica

Published: February 14, 2025

Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations.

Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations.

Journal: Antioxidants (Basel, Switzerland)

Published: October 25, 2024

Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.

Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.

Journal: Journal of translational medicine

Published: January 25, 2024

Showing 1-12 of 13

Last Updated: 09/26/2026